AXSOME THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
AXSOME THERAPEUTICS, INC. (AXSM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $34.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-23
- AXSOME THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $34.00M, a 42.08% decline from fiscal 2024.
- AXSOME THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $58.70M, a 50.51% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $39.00M, a 44.98% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $26.90M, a 45.77% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $34.00M 10-K · filed 2026-02-23 |
| 2024-12-31 | $58.70M 10-K · filed 2026-02-23 |
| 2023-12-31 | $39.00M 10-K · filed 2026-02-23 |
| 2022-12-31 | $26.90M 10-K · filed 2025-02-18 |
| 2021-12-31 | $49.60M 10-K · filed 2024-02-23 |
| 2020-12-31 | $39.70M 10-K · filed 2023-02-28 |
| 2019-12-31 | $27.00M 10-K · filed 2022-03-01 |
| 2018-12-31 | $12.50M 10-K · filed 2021-03-01 |
| 2017-12-31 | $6.70M 10-K · filed 2020-03-12 |
| 2016-12-31 | $14.30M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |